Tavlesse

RSS

fostamatinib

Authorised
This medicine is authorised for use in the European Union.

Overview

Tavlesse is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked.

Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily.

Tavlesse contains the active substance fostamatinib.

This EPAR was last updated on 11/02/2020

Authorisation details

Product details
Name
Tavlesse
Agency product number
EMEA/H/C/005012
Active substance
Fostamatinib disodium
International non-proprietary name (INN) or common name
fostamatinib
Therapeutic area (MeSH)
Thrombocytopenia
Anatomical therapeutic chemical (ATC) code
B02BX
Publication details
Marketing-authorisation holder
Rigel Pharmaceuticals B.V.
Date of issue of marketing authorisation valid throughout the European Union
09/01/2020
Contact address

Avenue Ceramique 223
6621 KX Maastricht
The Netherlands

Product information

09/01/2020 Tavlesse - EMEA/H/C/005012 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other systemic hemostatics

Therapeutic indication

Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

Assessment history

How useful was this page?

Add your rating